Physician profile
Dean T Halbert
NPI 1497758767
$1,346.57
in general payments reported to CMS, 2019-2025
18 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $44.28 · 2022: $70.10 · 2023: $310 · 2024: $272 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $819.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $257.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $212.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $163.83 | 2019-2025 | |
| Exact Sciences Corporation | $107.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $88.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $74.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $74.68 | 2019-2020 | |
| Abbvie INC. | $72.11 | 2022-2023 | |
| Amgen INC. | $64.53 | 2019-2024 | Repatha, Otezla |
| Dexcom, INC. | $46.92 | 2023-2025 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $31.70 | 2019 | |
| Astellas Pharma US INC | $28.48 | 2019-2024 | Veozah |
| Neurelis, INC. | $27.82 | 2025 | Valtoco |
| Radius Health, INC. | $25.52 | 2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $21.81 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.87 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2019 | |
| Edwards Lifesciences Corporation | $15.18 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Halbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.